The association between daily exacerbation symptoms and physical activity in patients with chronic obstructive pulmonary disease

Sarah Crook¹
Gilbert Büsching²
Stephan Keusch³
Stephan Wieser⁴
Alexander Turk³,⁵
Martin Frey¹
Milo A Puhan¹
Anja Frei¹

¹Department of Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland;
²Pulmonary Rehabilitation, Klinik Barmelweid, Barmelweid, Switzerland;
³Pulmonary Rehabilitation, Zürcher RehaZentrum Wald, Wald, Switzerland;
⁴Pulmonary Rehabilitation, Stadtspital Wald, Zurich, Switzerland;
⁵Department of Internal Medicine, See-Spital Horgen, Horgen, Switzerland

Background: Evidence from longitudinal studies on the impact of exacerbation symptoms on physical activity in chronic obstructive pulmonary disease (COPD) is lacking. The aim of this first exploratory study was to assess the association between exacerbation symptoms and physical activity, and to quantify the relative influence of specific symptoms.

Methods: We recruited COPD patients at high risk for exacerbations from 2 pulmonary rehabilitation clinics and 1 acute care clinic in Switzerland. For 3 months after discharge, patients completed a daily symptom diary on a smartphone application, the EXAcerbations of Chronic pulmonary disease Tool (EXACT), and wore a pedometer to measure daily steps. We used mixed-effects models to determine the association of daily steps with exacerbation symptoms.

Results: A total of 21 patients (Global Initiative for Chronic Obstructive Lung Disease grades 2–4) were enrolled for a mean of 94.4 days (standard deviation 4.2). The baseline median number of daily steps was 3,264.6 (interquartile range [IQR]: 1,851.3–4,784.1) and EXACT score was 37.0 (IQR: 30.9–41.4). A 12-point increase in EXACT score (indicating the start of an exacerbation) was statistically significantly associated with a decrease in daily steps of 653.3 (95% CI 969.7–336.9). Chest symptoms (tightness, discomfort and congestion) were more strongly associated with change in steps than breathlessness, and cough and sputum (z-value −4.5 vs −2.9 and −3.0).

Conclusion: This is the first study to show that, in a small cohort of COPD patients, increases in exacerbation symptoms were associated with a statistically and clinically significant reduction in daily physical activity. These results underscore the importance for symptom control and exacerbation prevention in COPD patients.

Keywords: longitudinal, management, step count, PRO, COPD, exacerbation, physical activity, symptoms

Introduction
Physical inactivity and exacerbations are both prominent features in chronic obstructive pulmonary disease (COPD) patients. They have been independently linked to outcomes including reduced health-related quality of life and increased morbidity and mortality.¹⁻⁴ Physical activity is potentially modifiable and known determinants include age, sex and exercise capacity;⁵ however, there is still much to learn about factors influencing physical activity levels.⁵

The relationship between exacerbations of COPD and physical activity is complex and currently not well understood. Low activity levels are a strong predictor of future severe exacerbations,⁶⁻¹⁰ however, physical activity is also known to be reduced during exacerbations.¹¹⁻¹³ Exacerbations are characterized by a worsening of the...
patient’s respiratory symptoms beyond the normal day-to-day variability; however, there are a few studies published on exacerbation symptoms in relation to physical activity. Exacerbation symptoms such as increased cough, sputum production, dyspnea and chest congestion could plausibly limit patients’ ability and/or willingness to be active. A recent systematic review found little evidence on the association between symptoms of COPD and objectively measured physical activity. One cross-sectional study reported statistically significant relationships between symptoms at different times of the day and subjectively assigned physical activity levels at baseline, and two studies found that reporting a sore throat was associated with a decline in physical activity during an exacerbation.

However, to our knowledge the impact of specific symptoms on changes in physical activity has not been explicitly assessed in longitudinal studies beyond limited periods of time (ie, during hospitalization). As exacerbation symptoms are known to naturally vary daily both inside and outside of exacerbation periods, it is important to capture the relationship between symptoms and physical activity longitudinally across the natural course of COPD. Therefore, we aimed to investigate the association between exacerbation symptoms and physical activity in COPD patients, and to quantify the relative influence of specific respiratory symptoms.

Methods

Study design and population

We recruited patients from 2 pulmonary rehabilitation clinics (Klinik Barmelweid and Zürcher RehaZentrum Wald) and 1 acute care clinic (Stadtpital Waid) in Switzerland (ClinicalTrials.gov: NCT02441725). In Switzerland, patients follow an inpatient rehabilitation program typically just after suffering from an exacerbation, and these patients usually have moderate to very severe COPD and multiple comorbidities. Thus, the patients included in this study were at high risk for additional exacerbations. We recruited patients from these settings as they were more likely to experience exacerbations during the study period. Patients from the pulmonary rehabilitation clinics already participated in the Validation of the 1-minute Sit-to-Stand Test in Patients with COPD (STAND-UP) study, with assessments during rehabilitation. They then decided whether to participate in the present study, the extended part of the STAND-UP study with additional assessments for 3 months after discharge. We included male and female patients ≥40 years of age with a COPD diagnosis according to Global Initiative for Chronic Obstructive Lung Disease criteria (post-bronchodilator forced expiratory volume in 1 s [FEV1]/forced vital capacity<70%). Patients were not included if the enrolling physician deemed them to have cognitive reading impairment and/or difficulties managing a smartphone or step counter that would limit their ability to complete the study assessments. Other exclusion criteria were lower limb joint surgery in the preceding 3 months, predominant neurological or musculoskeletal limitation to walking and inability to do five repetitions in the 1-minute sit-to-stand test.

This study was approved by all local ethics committees (Kantonale Ethikkommission Zürich [2014-0614] and Ethikkommission Nordwest-und ZentralSchweiz [2015-095]). All patients gave their written and oral informed consent to participate.

Daily assessments

Every evening before going to bed, participants completed the EXAcerbations of Chronic pulmonary disease Tool (EXACT) on a smartphone application, which is a validated symptom diary. The EXACT diary was developed and validated in a multisite process by the EXACT-PRO Initiative®. EXACT aims to provide a direct measure of exacerbation symptoms to evaluate the frequency, severity and duration of exacerbations in COPD patients. It asks about symptoms including cough, sputum production, dyspnea, chest symptoms (tightness, discomfort and congestion), tiredness, weakness, sleep disturbance and psychological state, and participants answer based on the symptoms experienced that day. The total EXACT score reflects the entirety of the symptoms on a scale of 0–100, with higher scores indicating more severe symptoms. An increase from baseline of 9 (for 3 days) or 12 points (for 2 days) is used to identify the start of an EXACT event (symptom-defined exacerbation). The Evaluating Respiratory Symptoms in COPD (E-RS) tool is a validated sub-scale of the EXACT, which reflects the specific respiratory symptoms experienced in three domains (breathlessness [scale 0–17, 5 items], cough and sputum [0–11, 3 items], and chest symptoms [0–12, 3 items]).

Participants were given a study smartphone to use if they did not have/wish to use their own.

Participants wore a pedometer (Fitbug Air; Fitbug, London, UK) on the hip for 3 months, at all times, except when sleeping or showering/swimming. They were asked to transfer the steps data each evening to the Fitbug smartphone application; if 1 or more days were missed, steps data were stored on the pedometer for 14 days. We trained participants to use the smartphone, the EXACT application, and to transfer the steps data. To maximize compliance, data transfers...
were monitored by study staff and participants were contacted if ≥3 days were missed.

**Event-based exacerbations and adverse events**

Exacerbations and adverse events were assessed with monthly telephone calls that were made to the patient by an experienced study nurse. The event-based definition required an increase in symptoms and an increase in dosage of or new prescription of systemic corticosteroids and/or antibiotics.

**Statistical analyses**

Data were expressed as mean ± standard deviation (SD) or median (interquartile range [IQR]), depending on the data distribution. We used linear mixed-effects models with daily step count as the outcome, with a random intercept by subjects and a random slope to account for the repeated measurements of exacerbation symptoms and step count within patients. To investigate exacerbation symptoms and physical activity, we fitted a model with the daily total EXACT score as the exposure variable and the random slope (model 1). We fitted three further models, one for each E-RS domain as the exposure variable and random slope, to investigate the relative influence of different respiratory symptoms (models 2–4). All models were adjusted for relevant covariates that we identified from clinical experience and previous research (age, sex, FEV1 [L], body mass index, number of exacerbations in the previous year, number of comorbidities, smoking status and functional exercise capacity [1-minute sit-to-stand test repetitions]). All models were estimated with an unstructured covariance structure to allow for correlation between the two random effects. Due to heteroskedasticity of the residuals, we used a robust variance estimator to estimate the standard errors. For model 1, we estimated the change in daily steps in relation to a change in EXACT score of 12 points and 9 points, and for all models we calculated the z-value and Bayesian Information Criterion (BIC). Analyses were conducted using Stata (version 14.1; StataCorp, College Station, TX, USA).

**Results**

**Population characteristics**

In total, 22 patients from 2 pulmonary rehabilitation clinics (n=19) and 1 acute care hospital (n=3) with moderate to very severe COPD were included in the study. One patient withdrew from the study after baseline assessment due to a lack of motivation. Patients were followed up for a mean of 94.4 (SD 4.2) days. Table 1 summarizes the baseline patient characteristics.

**Table 1** Patient characteristics at discharge from pulmonary rehabilitation or acute care

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients (N=21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, male, n (%)</td>
<td>14 (66.7)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>63.0 (9.9)</td>
</tr>
<tr>
<td>FEV1 (L)</td>
<td>1.2 (0.4)</td>
</tr>
<tr>
<td>FEV1 % predicted</td>
<td>40.8 (14.3)</td>
</tr>
<tr>
<td>BMI (kgm−2)</td>
<td>23.9 (6.1)</td>
</tr>
<tr>
<td>Smoking status, n (%)</td>
<td></td>
</tr>
<tr>
<td>Never-smoker</td>
<td>1 (4.8)</td>
</tr>
<tr>
<td>Former smoker</td>
<td>15 (71.4)</td>
</tr>
<tr>
<td>Current smoker</td>
<td>5 (23.8)</td>
</tr>
<tr>
<td>GOLD grade, n (%)</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>5 (23.8)</td>
</tr>
<tr>
<td>III</td>
<td>8 (38.1)</td>
</tr>
<tr>
<td>IV</td>
<td>8 (38.1)</td>
</tr>
<tr>
<td>Exacerbations in previous year</td>
<td>2.3 (1.9)</td>
</tr>
<tr>
<td>Number of comorbidities per patient</td>
<td>3.4 (1.9)</td>
</tr>
<tr>
<td>Comorbidity type, n</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular disease group</td>
<td>25</td>
</tr>
<tr>
<td>Cerebrovascular disease group</td>
<td>1</td>
</tr>
<tr>
<td>Metabolic disease group</td>
<td>1</td>
</tr>
<tr>
<td>Musculoskeletal disease group</td>
<td>5</td>
</tr>
<tr>
<td>Psychiatric disease group</td>
<td>6</td>
</tr>
<tr>
<td>Other diseases</td>
<td>31</td>
</tr>
<tr>
<td>I-min STS test repetitions</td>
<td>22.4 (8.0)</td>
</tr>
</tbody>
</table>

**Baseline outcomes and adverse events**

Participants had a mean of 85.3 (SD 17.3) days of step counts and 77.7 (SD 20.1) days of EXACT scores. Eleven event-based exacerbations (9 home-based and 2 hospital-based) were experienced by 9 patients, and 10 adverse events were experienced by 6 patients (all unrelated to the study assessments, non-serious and did not require hospitalization). The median (IQR) baseline daily step count was 3,264.6 (1,851.3–4,784.1) and EXACT score was 37.0 (30.9–41.4), calculated as the median daily value of a stable period of 7 days (first week after discharge for pulmonary rehabilitation patients and second week after discharge for acute care patients). The EXACT scoring algorithm used to determine a symptom-defined exacerbation did not detect >50% of the event-based exacerbations in our data. These results reflect those found previously in an independent validation of the EXACT scoring algorithm. Therefore, we did not consider symptom-defined exacerbations in the interpretation of our data.

**Exacerbation symptoms**

Table 2 shows the adjusted coefficient for the association between daily EXACT score and daily step count, along
with the coefficients for each covariate. A 9-point increase in daily EXACT score was associated with a significant decrease of −490.0 (95% CI −727.3 to −252.7) in the number of daily steps. A 12-point increase in daily EXACT score was associated with a decrease of −653.3 (95% CI −969.7 to −336.9) in the number of daily steps. In model 1, the adjusted intraclass correlation coefficient was 0.25. This means that most of the variation in daily steps (75%) was within individuals and only 25% was between individuals. The fitted regression lines from model 1 show the predicted association between daily exacerbation symptoms and daily steps for each patient (Figure 1). There is variation between patients in the estimated intercept and slope of the association. There also appears to be a weaker association (slope more horizontal) at higher numbers of steps, and more between-patient variation at lower EXACT scores (fewer symptoms).

All three domains of the E-RS were independently significantly associated with the number of daily steps in adjusted models (Table 3). The standardized regression coefficients show that the effect of chest symptoms on the number of daily steps was stronger than the effects of breathlessness, and cough and sputum (adjusted z-value −4.5 vs −2.9 and −3.0, respectively). The BIC was lowest for the model with chest symptoms, indicating there is a better fit of the data (lower BIC) than the models with the breathlessness and cough and sputum domains (breathlessness +17 and cough and sputum +12, compared to chest symptoms).

Individual patient courses of daily steps and daily EXACT scores over the 3-month study period are shown in Figure 2. Step count and EXACT score are presented as 5-day moving averages to facilitate the visualization of trends.

**Discussion**

In this novel study, we found that an increase in exacerbation symptoms was strongly associated with a reduction in physical activity. The strength of this association was found to differ between patients. Chest symptoms (tightness, discomfort and congestion) were more strongly associated with changes in physical activity than other respiratory symptoms.

To our knowledge, this is the first study to investigate the impact of exacerbation symptoms on changes in physical activity.
Table 3 Adjusted associations of each respiratory symptom domain with daily physical activity, estimated from individual models (models 2–4)

<table>
<thead>
<tr>
<th>E-RS symptom domain score</th>
<th>Effect</th>
<th>95% CI</th>
<th>z-value</th>
<th>P-value</th>
<th>BIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breathlessness(^a) (model 2)</td>
<td>−153.4</td>
<td>−257.8 to −49.0</td>
<td>−2.9</td>
<td>0.004</td>
<td>25,748</td>
</tr>
<tr>
<td>Cough and sputum(^b) (model 3)</td>
<td>−127.8</td>
<td>−212.7 to −42.9</td>
<td>−3.0</td>
<td>0.003</td>
<td>25,743</td>
</tr>
<tr>
<td>Chest symptoms(^c) (model 4)</td>
<td>−187.7</td>
<td>−268.8 to −106.7</td>
<td>−4.5</td>
<td>&lt;0.001</td>
<td>25,731</td>
</tr>
</tbody>
</table>

Notes: All 3 models were adjusted for the same confounders as in model 1; all effects are per 1-point increase. Breathlessness score range: 0–17 points, cough and sputum score range: 0–11 points, chest symptoms score range: 0–12 points; chest symptoms include chest tightness, discomfort and congestion.

Abbreviations: BIC, Bayesian Information Criterion; E-RS, Evaluating Respiratory Symptoms in chronic obstructive pulmonary disease.

Activity on a day-to-day basis. Patients were less likely to be active when they were experiencing exacerbation symptoms, resulting in a strong and statistically significant reduction in the number of steps walked. A clinically important increase in symptoms of exacerbation (an increase in total EXACT score of 12 points)\(^20\) was associated with a reduction of 653 steps on that day. This reduction can be considered as clinically important as it exceeds the lower threshold of the recently estimated minimum important difference for daily step count (600–1,100 steps).\(^25\)

Figure 2 (Continued)
Figures 1 and 2 indicate that the strength of the association between exacerbation symptoms and physical activity differs among patients. Reasons for these inter-patient differences are currently unclear; however, there may be some influence from the average number of daily steps or overall variability in the number of daily steps, as suggested by the differences between estimated intercepts and slopes (Figure 1). It could be that patients with on average higher steps or with more variation in steps are influenced by exacerbation symptoms in a stronger manner, as their activity levels are able to reduce more than those who have an already low level, or it could be that another factor, such as severity of COPD, is driving the between-patient differences. One previous study found that patients with more daily and weekly variability in symptoms were more affected in their daily activities. However, this would need to be investigated in a larger study of COPD patients. The association between EXACT score and number of steps is evident in some patients but is not always obvious (Figure 2). Patient 4 is an example of a seemingly consistent negative correlation, whereas patient 2 appears to show little correlation. There is marked variability in exacerbation symptoms even in periods with no event-based exacerbation, which corresponds with a previous study that found daily and weekly variability in exacerbation symptoms in non-exacerbation periods.

Previous research has shown that breathlessness and cough and sputum production are more commonly reported by COPD patients than chest discomfort and tightness. More patients also perceived increasing cough, breathlessness and sputum to have a high impact on wellbeing than chest pain (42%, 37% and 35% vs 20% of respondents). However, in our patients we found that an increase in chest symptoms had a more substantial impact on physical activity than breathlessness or cough and sputum. We can only speculate about the specific underlying cause of these
Daily symptoms of exacerbation and physical activity in COPD

One limitation of our study is that there was some missing data for daily steps and EXACT scores, which is difficult to avoid in longitudinal studies with repeated assessments. In some instances, the data were missing due to technical problems with the smartphone and/or application (missing completely at random). However, the reason for missingness was often not clear. While the mixed-effects model accounts for missing repeated-measures data, it should be considered that there may be important information missing when the reason for missing values was related to the outcome (ie, patient not completing the EXACT questionnaire during an exacerbation). A second limitation is the small sample size, which limits our ability to investigate the association further. This is partly explained by the substantial commitment patients need to have to report symptoms daily and wear a pedometer for 3 months. Despite this, we used longitudinal methods that enabled us to make use of the large amount of data collected over the study period. In total, model 1 utilized around 1,500 observations. Therefore, we consider our results to be valid in this sample, and our results may be generalizable to other patients with moderate to very severe COPD following an exacerbation. From visual inspection of individual patient data, we generated further hypotheses concerning the relationship between exacerbation symptoms and physical activity, although the small number of clusters limited our ability to explore these. Our use of pedometers to measure physical activity rather than accelerometers could be considered as a limitation since pedometers may underestimate steps in moderate to very severe COPD patients and we do not have additional information on the intensity or duration of activity. However, as the patients in our study all had moderate to very severe COPD, it is likely that bias from underestimation of steps is similar across patients. Therefore, we decided to use the Fitbug Air as a simple tool for assessing physical activity, which has previously been used in studies of COPD patients, as it is more valid than self-reported questionnaires, has less burden for patients and can record activity over a longer period than accelerometers.

Conclusion

An increase in daily exacerbation symptoms was statistically and clinically significantly associated with increasing physical inactivity in our population of COPD patients. Respiratory chest symptoms may be more important in determining physical inactivity levels than other respiratory symptoms. These novel results give us additional insight into the behavior of COPD patients in relation to changes in physical activity and emphasize the need for symptom control and prevention of exacerbations.

Acknowledgments

The authors would like to thank the study nurses Ursula Schafroth (University of Zurich, Zurich, Switzerland) and Luise Wiedemann (Zürcher RehaZentrum Wald, Wald, Switzerland) for their work during the conduct of the study. We also thank Verein Lunge Zürich for providing the funding for the STAND-UP study. The funding body had no role in the design of the study, the collection and analysis of the data or the preparation of the manuscript. We would also like to thank Swisscom AG for donating the mobile phone SIM cards that were used for data collection during the study and Professor Doctor Ulf Blanke (Wearable Computing Laboratory, ETH Zurich, Swiss Federal Institute of Technology, Zurich, Switzerland) for developing the smartphone application and software for collecting the EXACT and steps data.
Disclosure
The authors report no conflicts of interest in this work.

References